An experience of using Laennec in patients at high risk of a cytokine storm with COVID-19 and hyperferritinemia

The probability of formation of the so-called “cytokine storm” accompanied by an avalanche-like growth of inflammatory markers – interleukins (IL)-1β, -6, interferon-γ, tumor necrosis factor-α, C-reactive protein (CRP), ferritin, etc. is high at a heavy current of COVID-19. In the absence of adequate treatment in the development of “cytokine storm” increases the risk of death, especially against the background of comorbid pathology. Methods. In April-May 2020, patients (n = 28: 12 men, 16 women; age 39 – 86 years) with long, chronic COVID-19 course were under observation, hospitalized on critical days of the disease. All patients reported anosmia, cough with poor sputum, signs of conjunctivitis. The patients had chronic diseases (n = 22: coronary heart disease, diabetes mellitus type 2, scleroderma). All patients were given standard therapy; half (n = 14) were additionally prescribed Laennec for 3 – 10 days (6 ml per 350 ml of 0.9% NaCl solution, intravenous infusion for the first 3 days, from day 4 – 6 ml per 250 ml of 0.9% NaCl solution) until stable remission is achieved. Results. The majority state (n = 25) stabilized; several patients died in the control group (n = 3; p = 0.067). In spite of the state stabilization, no reliable positive dynamics was noted in the control group for the tested parameters. Initially, liver dysfunction (level of alanine aminotransferase (ALT) – 113 ± 121, aspartate aminotransferase (AST) – 90.8 ± 87) was registered in 71% of patients, 8 units/l) and high risk of “cytokine storm” development (ferritin levels in men – 480 – 1 072 µg/l, in women – 274.7 – 493 µg/l, C-reactive protein – 5.0 – 52.6 mg/l, lymphocytes – < 25%). Positive clinical dynamics, a decrease in the level of ferritin (–282 µg/l – in men, –80 µg/l – in women; p = 0.039), an increase in blood oxygenation to normal values (p = 0.0029), a decrease in the area of lung injury according to CT data (on average – 10%); p = 0.0027), increase in relative lymphocyte content (+8%; p = 0.04), normalization of markers of liver dysfunction (AST, ALT), creatinine and systolic blood pressure (p < 0.05) were observed on prescription of Laennec. All patients who received Laennec recovered within 3 – 15 days from the start of the drug and were discharged with a negative test for SARS-CoV-2. Conclusion. Health condition is significantly improved, a wide range of hepatoprotective, immunomodulatory and regenerative effects are observed when the polypeptide Laennec is included in the complex therapy in patients with severe COVID-19. Laennec should be used primarily in patients with liver pathology, diabetes mellitus type 2, coronary heart disease, including high ferritin levels.

COVID-19 therapy, comorbid conditions, ferritinemia, Laennec, predictive modeling, intellectual data analysis

1. Tang N., Li D., Wang X., Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J. Thromb. Haemost. 2020; 18 (4): 844–847. DOI: 10.1111/jth.14768.

2. Liu C., Jiang Z.C., Shao C.X. et al. [Preliminary study of the relationship between novel coronavirus pneumonia and liver function damage: a multicenter study]. Zhonghua Gan Zang Bing Za Zhi. 2020; 28 (2): 148–152. DOI: 10.3760/cma.j.issn.1007-3418.2020.02.003 (in Chinese).

3. Gromova O.A., Torshin I.Yu. [The importance of zinc in maintaining the activity of antiviral innate immunity proteins: analysis of publications on COVID-19]. Profilakticheskaya meditsina. 2020; 23 (3): 131–139. DOI: 10.17116/profmed202023031131 (in Russian).

4. Stefanyuk O.V., Lazebnik L.B. [The defeat of the digestive system during infection SARS-CoV-2]. Eksperimental’naya i klinicheskaya gastroenterologiya. 2020; 175 (3): 4–9. DOI: 10.31146/1682-8658-ecg-175-3-4-9 (in Russian).

5. Jin X., Lian J.S., Hu J.H. et al. Epidemiological, clinical and virological characteristics of 74 cases of coronavirusinfected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut. 2020; 69 (6): 1002–1009. DOI: 10.1136/gutjnl-2020-320926.

6. Torshin I.Yu., Gromova O.A. [Worldwide experience of the therapeutic use of the human placental hydrolytes]. Eksperimental’naya i klinicheskaya gastroenterologiya. 2019; 170 (10): 79–89. DOI: 10.31146/1682-8658-ecg-170-10-7989 (in Russian).

7. Torshin I.Yu., Rudakov K.V. On the theoretical basis of metric analysis of poorly formalized problems of recognition and classification. Pattern Recognit. Image Anal. 2015; 25 (4): 577–587. DOI: 10.1134/s1054661815040252.

8. Torshin I.Yu., Rudakov K.V. Topological data analysis in materials science: the case of high-temperature cuprate superconductors. Pattern Recognit. Image Anal. 2020; 30 (2): 264–276. DOI: 10.1134/S1054661820020157.

9. Torshin I.Yu., Rudakov K.V. On the procedures of generation of numerical features over partitions of sets of objects in the problem of predicting numerical target variables. Pattern Recognit. Image Anal. 2019; 29 (4): 654–667. DOI: 10.1134/S1054661819040175.

10. Gromova O.A., Torshin I.Yu., Kobalava Z.D. et al. [Deficit of magnesium and states of hypercoagulation: intellectual analysis of data obtained from a sample of patients aged 18–50 years from medical and preventive facilities in Russia]. Kardiologiia. 2018; 58 (4): 20–32. DOI: 10.18087/cardio.2018.4.10106 (in Russian).

11. Torshin I.Yu., Gromova O.A., Tetruashvili N.K. et al. [Metric analysis of comorbidity ratios between miscarriage, endometriosis, menstrual disorders, and micronutrient provision in screening reproductive-aged women]. Akusherstvo i ginekologiya. 2019; (5): 160–173. DOI: 10.18565/aig.2019.5 (in Russian).

12. Chen C., Chen C., Yan J.T. et al. [Analysis of myocardial injury in patients with COVID-19 and association between concomitant cardiovascular diseases and severity of COVID19]. Zhonghua Xin Xue Guan Bing Za Zhi. 2020; 48 (7): 567–571. DOI: 10.3760/cma.j.cn112148-20200225-00123 (in Chinese).

13. Henry B.M., de Oliveira M.H.S., Benoit S., Plebani M. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin. Chem. Lab. Med. 2020; 58 (7): 1021–1028. DOI: 10.1515/cclm-2020-0369.

14. Zeng F., Huang Y., Guo Y. et al. Association of inflammatory markers with the severity of COVID-19: a meta-analysis. Int. J. Infect. Dis. 2020; 96: 467–474. DOI: 10.1016/j.ijid.2020.05.055.

15. Li L.Q., Huang T., Wang Y.Q. et al. COVID-19 patients’ clinical characteristics, discharge rate, and fatality rate of meta-analysis. J. Med. Virol. 2020; 92 (6): 577–583. DOI: 10.1002/jmv.25757.

16. Torshin I.Yu., Gromova O.A., Dibrova E.A. et al. [Peptides in the composition of the drug Laennec, potentiating its antiviral effects in the treatment of atopic dermatitis of herpes infection]. Rossiyskiy allergologicheskiy zhurnal. 2018; 15 (1–1): 82–90. DOI: 10.36691/rja191 (in Russian).

17. Cheng Y., Luo R., Wang K. et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int. 2020; 97 (5): 829–838. DOI: 10.1016/j.kint.2020.03.005.

18. Feng G., Zheng K.I., Yan Q.Q. et al. COVID-19 and liver dysfunction: current insights and emergent therapeutic strategies. J. Clin. Transl. Hepatol. 2020; 8 (1): 18–24. DOI: 10.14218/JCTH.2020.00018.

19. Johnson C.A., Levey A.S., Coresh J. et al. Clinical practice guidelines for chronic kidney disease in adults: Part II. Glomerular filtration rate, proteinuria, and other markers. Am. Fam. Physician. 2004; 70 (6): 1091–1097.

20. Egorova E.Y., Torshin I.Y., Gromova O.A., Martynov A.I. [The use of cardiointervalography for diagnostic screening and evaluation of the efficiency of correction of magnesium deficiency and comorbid conditions]. Terapevticheskiy arkhiv. 2015; 87 (8): 16–28. DOI: 10.17116/terarkh201587816-28 (in Russian).

21. Gromova O.A., Torshin I.Yu., Volkov A.Yu. et al. [Preparation Laennec: elemental composition and key role in the pharmacological action]. Plasticheskaya khirurgiya i kosmetologiya. 2011; (2): 327–333 (in Russian).